It is widely believed that the first use of myeloid colonystimulating factors in humans was sargramostim (GM-CSF) in victims of the Goiania, Brazil radiation accident in 1987.
1 GM-CSF was later approved by US FDA in 1991, as was filgrastim (G-CSF). However, with the recent release of previously classified documents from the ex-Soviet Union, we are now able to correct the historical record.
In May 1986, we and colleagues at Clinical Hospital 6 in Moscow treated about 200 emergency personnel exposed to high-dose radiation at the Chernobyl Nuclear Power Facility.
2 Six weeks after the accident, three persons who received an estimated dose of 5 Gy and only supportive care continued to have severe granulocytopenia with life-threatening lung disease, likely from radiation pneumonitis and infection(s), which was unresponsive to antibiotics and anti-fungal and anti-viral drugs.
We considered therapy with GM-CSF, which had been successfully tested in animals, including sub-human primates, but not in humans. We contacted Sandoz Pharma (Basel; Dr Angelica Stern) asking for GM-CSF; the company agreed. One of us (AV) invoked his authority as a member of the special Soviet Government Commission, which enabled him to make extraordinary medical decisions in response to the Chernobyl accident. The GM-CSF was shipped to Moscow.
We decided to test the safety of GM-CSF by injecting a 10-fold higher dose than recommended in sub-human primates. AV received the drug without immediate adverse effects. However, within a few minutes, he complained of rapidly intensifying severe pain in the sacrum, which required i.v. morphine. The pain resolved rapidly. RPG's injection was without complications.
(BM pain is now a well-recognized complication of GM-and G-CSF injections, but, curiously, the monkeys had not remarked upon this; perhaps they sought revenge.)
We monitored the effects, including that of increased granulocytes, over 48 h; no other complications were observed. AV used his authority to approve giving GM-CSF to the three persons specified above after obtaining informed consent regarding potential risks and benefits of therapy (including the limited prior human experience).
One person died of progressive pneumonia within 2 days before any effect of GM-CSF could be detected. The other two had recovery of normal hematopoiesis over several weeks and survived. The authors have not experienced adverse events after more than 25 years. Whether they were normal when they received GM-CSF is difficult to say.
